Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 68

1.

The Phylogeny and Biological Function of Gastric Juice-Microbiological Consequences of Removing Gastric Acid.

Martinsen TC, Fossmark R, Waldum HL.

Int J Mol Sci. 2019 Nov 29;20(23). pii: E6031. doi: 10.3390/ijms20236031. Review.

2.

Adverse Effects of Proton Pump Inhibitors-Evidence and Plausibility.

Fossmark R, Martinsen TC, Waldum HL.

Int J Mol Sci. 2019 Oct 21;20(20). pii: E5203. doi: 10.3390/ijms20205203. Review.

3.

Role of Autoimmune Gastritis in Gastric Cancer.

Waldum HL, Fossmark R.

Clin Transl Gastroenterol. 2019 Sep;10(9):e00080. doi: 10.14309/ctg.0000000000000080. No abstract available.

4.

Hepatic micrometastases outside macrometastases are present in all patients with ileal neuroendocrine primary tumour at the time of liver resection.

Fossmark R, Balto TM, Martinsen TC, Grønbech JE, Munkvold B, Mjønes PG, Waldum HL.

Scand J Gastroenterol. 2019 Aug;54(8):1003-1007. doi: 10.1080/00365521.2019.1647281. Epub 2019 Aug 1.

PMID:
31368380
5.

Editorial: mesalamine and mucosal microbiome in quiescent ulcerative colitis-what can we learn? Authors' reply.

Olaisen M, Fossmark R.

Aliment Pharmacol Ther. 2019 Jun;49(12):1532. doi: 10.1111/apt.15285. No abstract available.

PMID:
31134653
6.

Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.

Olaisen M, Spigset O, Flatberg A, Granlund AVB, Brede WR, Albrektsen G, Røyset ES, Gilde B, Sandvik AK, Martinsen TC, Fossmark R.

Aliment Pharmacol Ther. 2019 May;49(10):1301-1313. doi: 10.1111/apt.15227. Epub 2019 Mar 20.

7.

Types of Gastric Carcinomas.

Waldum HL, Fossmark R.

Int J Mol Sci. 2018 Dec 18;19(12). pii: E4109. doi: 10.3390/ijms19124109. Review.

8.

Not only stem cells, but also mature cells, particularly neuroendocrine cells, may develop into tumours: time for a paradigm shift.

Waldum HL, Öberg K, Sørdal ØF, Sandvik AK, Gustafsson BI, Mjønes P, Fossmark R.

Therap Adv Gastroenterol. 2018 May 27;11:1756284818775054. doi: 10.1177/1756284818775054. eCollection 2018. Review.

9.

Proton pump inhibitors (PPIs) may cause gastric cancer - clinical consequences.

Waldum HL, Sørdal Ø, Fossmark R.

Scand J Gastroenterol. 2018 Jun;53(6):639-642. doi: 10.1080/00365521.2018.1450442. Epub 2018 May 31. Review.

PMID:
29852782
10.

Proton pump inhibitors and gastric cancer: a long expected side effect finally reported also in man.

Waldum HL, Fossmark R.

Gut. 2018 Jan;67(1):199-200. doi: 10.1136/gutjnl-2017-315629. Epub 2017 Nov 20. No abstract available.

11.

Expression of the Cholecystokinin-B Receptor in Neoplastic Gastric Cells.

Mjønes P, Nordrum IS, Sørdal Ø, Sagatun L, Fossmark R, Sandvik A, Waldum HL.

Horm Cancer. 2018 Feb;9(1):40-54. doi: 10.1007/s12672-017-0311-8. Epub 2017 Oct 4.

12.

The cytoprotective protein clusterin is overexpressed in hypergastrinemic rodent models of oxyntic preneoplasia and promotes gastric cancer cell survival.

Vange P, Bruland T, Doseth B, Fossmark R, Sousa MML, Beisvag V, Sørdal Ø, Qvigstad G, Waldum HL, Sandvik AK, Bakke I.

PLoS One. 2017 Sep 13;12(9):e0184514. doi: 10.1371/journal.pone.0184514. eCollection 2017.

13.

Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.

Boyce M, Moore AR, Sagatun L, Parsons BN, Varro A, Campbell F, Fossmark R, Waldum HL, Pritchard DM.

Br J Clin Pharmacol. 2017 Mar;83(3):466-475. doi: 10.1111/bcp.13146. Epub 2016 Nov 21.

14.

The gastrin receptor antagonist netazepide (YF476) in patients with type 1 gastric enterochromaffin-like cell neuroendocrine tumours: review of long-term treatment.

Sagatun L, Mjønes P, Jianu CS, Boyce M, Waldum HL, Fossmark R.

Eur J Gastroenterol Hepatol. 2016 Nov;28(11):1345-1352.

PMID:
27682220
15.

Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice.

Aasarød KM, Ramezanzadehkoldeh M, Shabestari M, Mosti MP, Stunes AK, Reseland JE, Beisvag V, Eriksen EF, Sandvik AK, Erben RG, Schüler C, Boyce M, Skallerud BH, Syversen U, Fossmark R.

J Endocrinol. 2016 Aug;230(2):251-62. doi: 10.1530/JOE-16-0017. Epub 2016 Jun 20.

PMID:
27325243
16.

Follow-up of patients with ECL cell-derived tumours.

Sagatun L, Fossmark R, Jianu CS, Qvigstad G, Nordrum IS, Mjønes P, Waldum HL.

Scand J Gastroenterol. 2016 Nov;51(11):1398-405. doi: 10.3109/00365521.2016.1169588. Epub 2016 Jun 16.

PMID:
27309188
17.

Adverse Effects of Proton Pump Inhibitors in Chronic Kidney Disease.

Ness-Jensen E, Fossmark R.

JAMA Intern Med. 2016 Jun 1;176(6):868. doi: 10.1001/jamainternmed.2016.1857. No abstract available.

PMID:
27273497
18.

ECL-cell carcinoids and carcinoma in patients homozygous for an inactivating mutation in the gastric H(+) K(+) ATPase alpha subunit.

Fossmark R, Calvete O, Mjønes P, Benitez J, Waldum HL.

APMIS. 2016 Jul;124(7):561-6. doi: 10.1111/apm.12546. Epub 2016 May 6.

PMID:
27150581
19.

PAI-1 deficiency increases the trophic effects of hypergastrinemia in the gastric corpus mucosa.

Fossmark R, Rao S, Mjønes P, Munkvold B, Flatberg A, Varro A, Thommesen L, Nørsett KG.

Peptides. 2016 May;79:83-94. doi: 10.1016/j.peptides.2016.03.016. Epub 2016 Mar 30.

PMID:
27038741
20.

Does long-term profound inhibition of gastric acid secretion increase the risk of ECL cell-derived tumors in man?

Waldum HL, Hauso Ø, Brenna E, Qvigstad G, Fossmark R.

Scand J Gastroenterol. 2016 Jul;51(7):767-73. doi: 10.3109/00365521.2016.1143527. Epub 2016 Feb 12. Review.

PMID:
26872579

Supplemental Content

Loading ...
Support Center